Publication:
Barakol, a natural anxiolytic inhibits striatal dopamine release but not uptake in vitro

Simple item page
dc.contributor.authorThongsaard W.
dc.contributor.authorPongsakorn S.
dc.contributor.authorSudsuang R.
dc.contributor.authorBennett G.W.
dc.contributor.authorKendall D.A.
dc.contributor.authorMarsden C.A.
dc.date.accessioned2021-04-05T04:33:44Z
dc.date.available2021-04-05T04:33:44Z
dc.date.issued1997
dc.date.issuedBE2540
dc.description.abstractThe present study investigated the effects of barakol on the in vitro release of endogenous and radiolabelled dopamine from rat striatal slices in comparison with the dopamine receptor agonist, quinelorane dihydrochloride (1 μM) and pergolide methanesulfonate (100 μM), and the dopamine receptor antagonist, S(-)-eticlopride hydrochloride (10 μM) using a semi-superfusion method and high-performance liquid chromatography with electrochemical detector measurement of endogenous dopamine. Barakol (1, 10 and 100 μM) reduced K+-stimulated endogenous dopamine release as did the dopamine D2 receptor agonists but had no effect on [3H]dopamine release. The inhibition of barakol (10 μM) on K+-stimulated endogenous dopamine release was antagonised by a dopamine D2 receptor antagonist, eticlopride. Barakol (0.1 nM-10 μM) had no effect on [3H]dopamine uptake except at the highest concentration (100 μM) when inhibition was observed. The results indicate that barakol might act as a dopamine agonist to inhibit endogenous dopamine release without a change in dopamine uptake.
dc.format.mimetypeapplication/pdf
dc.identifier.citationEuropean Journal of Pharmacology. Vol 319, (1997), p.157-164
dc.identifier.doi10.1016/S0014-2999(96)00850-3
dc.identifier.issn142999
dc.identifier.other2-s2.0-0031032513
dc.identifier.urihttps://hdl.handle.net/20.500.14740/7309
dc.rights.holderScopus
dc.subject.otherBarakol
dc.subject.otherDopamine receptor stimulating agent
dc.subject.otherEticlopride
dc.subject.otherPergolide mesilate
dc.subject.otherQuinelorane
dc.subject.otherUnclassified drug
dc.subject.otherAnimal tissue
dc.subject.otherArticle
dc.subject.otherBrain slice
dc.subject.otherControlled study
dc.subject.otherDopamine release
dc.subject.otherDopamine uptake
dc.subject.otherMale
dc.subject.otherNonhuman
dc.subject.otherPriority journal
dc.subject.otherRat
dc.subject.otherAnimals
dc.subject.otherAnti-Anxiety Agents
dc.subject.otherBenzopyrans
dc.subject.otherCalcium
dc.subject.otherCassia
dc.subject.otherChromatography, High Pressure Liquid
dc.subject.otherDopamine
dc.subject.otherDopamine Agonists
dc.subject.otherElectrochemistry
dc.subject.otherMale
dc.subject.otherNeostriatum
dc.subject.otherPergolide
dc.subject.otherPhenalenes
dc.subject.otherPlant Extracts
dc.subject.otherPlants, Medicinal
dc.subject.otherPotassium
dc.subject.otherRats
dc.subject.otherReceptors, Dopamine D2
dc.titleBarakol, a natural anxiolytic inhibits striatal dopamine release but not uptake in vitro
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-0031032513&doi=10.1016%2fS0014-2999%2896%2900850-3&partnerID=40&md5=d480b100d07b0a8ee03d63404f839661

Files

Collections

Scopus: Year 1983-2021